IP Library Patent Application 14290540
Patent Application
App. No. 14/290,540

ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/290,540
Abstract

A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Claims (9)

58 . An oral pharmaceutical composition comprising testosterone undecanoate solubilized in a carrier comprising at least one lipophilic surfactant and at least one hydrophilic surfactant in a total lipophilic surfactant to total hydrophilic surfactant ratio (w/w) falling in the range of about 6:1 to 3.5:1, wherein said solubilized testosterone undecanoate comprises 18 to 22 percent by weight of the composition.

59 . The oral pharmaceutical composition of claim 58 in which the at least one hydrophilic surfactant comprises Cremophor RH 40 (polyoxyethyleneglycerol-trihydroxy-stearate).

60 . The oral pharmaceutical composition of claim 58 in which the at least one lipophilic surfactant comprises oleic acid.

61 . The oral pharmaceutical composition of claim 58 in which the testosterone undecanoate is solubilized in a carrier substantially free of ethanol.

62 . The oral pharmaceutical composition of claim 58 which comprises 15 to 17 percent by weight of the at least one hydrophilic surfactant.

63 . The oral pharmaceutical composition of claim 58 which comprises 50 to 55 percent by weight of the at least one lipophilic surfactant.

64 . A method of treating testosterone deficiency or its symptoms comprising orally administering to a subject suffering from testosterone deficiency or its symptoms an effective amount of a pharmaceutical composition comprising testosterone undecanoate solubilized in a carrier comprising at least one lipophilic surfactant and at least one hydrophilic surfactant in a total lipophilic surfactant to total hydrophilic surfactant ratio (w/w) falling in the range of about 6:1 to 3.5:1 to provide an average serum testosterone concentration at steady state falling in the range of about 300 to about 1100 ng/dL.

65 . The method of claim 64 in which the composition is administered once daily.

66 . The method of claim 64 in which the composition is administered twice daily.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: CLARUS THERAPEUTICS, INC.
To: TOLMAR, INC.
Reel/Frame 061774/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2015
From: DUDLEY, ROBERT E.; CONSTANTINIDES, PANAYIOTIS P.
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 036416/0438 →